Lilly Exits CVS Drug Plan for Employees After Novo Nordisk Deal for Wegovy

Eli Lilly is ending its drug plan with CVS Health for its employees after CVS limited access to Lilly's weight loss drug Zepbound in favor of Novo Nordisk's Wegovy. Lilly's Wegovy competitor, Zepbound, was launched in September. Lilly is reportedly shifting its employees to a new plan to maintain access to Zepbound. The move comes after CVS's decision to limit Zepbound access in favor of Wegovy, which has been a blockbuster for Novo Nordisk.